Liquid Biopsy Market: Global Industry Growth, Trends, Opportunities, and Forecast

The Liquid Biopsy Market is witnessing strong growth as healthcare providers increasingly seek non-invasive approaches for cancer detection, treatment monitoring, and personalized medicine. According to Market Research Future, the market was valued at USD 9.1 billion in 2024 and is projected to reach USD 27.34 billion by 2035, registering a CAGR of 10.52% during 2025–2035.

Liquid biopsy analyzes biomarkers such as circulating tumor DNA, circulating tumor cells, and extracellular vesicles from biological fluids including blood and urine. Compared with conventional tissue biopsy, liquid biopsy can offer a less invasive approach while supporting repeated testing and monitoring of tumor changes.

The increasing global incidence of cancer is a major factor driving demand for advanced diagnostic technologies. Growing adoption of precision medicine is also encouraging healthcare professionals to use molecular information to guide treatment decisions.

Technological advancements in next-generation sequencing, digital PCR, microfluidics, and biomarker analysis are further expanding the potential applications of liquid biopsy. Oncology remains a major application area, while blood-based testing continues to dominate due to its accessibility and clinical utility.

North America currently leads the global market, while Asia-Pacific represents an important growth opportunity because of increasing healthcare investment and awareness of advanced diagnostics.

Read More
Lukoon https://lukoon.com